Maximiliano Arroyo, MD
Cardiovascular Disease · Jonesboro, ARNPI 1437376548
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (30.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 66.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $17,887 and has fallen 86.8% since, to $2,368 in 2025. Among cardiovascular disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $107.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$31K
- Abiomed$11K
- Abbott$1K
- Avinger Inc.$697
- Johnson & Johnson$461
- Shockwave Medical, Inc$448
- plus $2K from 22 others
Across 100 payments — averaging $5064.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$255K
- Boston Scientific$252K
What the payments were for
- Consulting fees$12,50027%
- Speaking & faculty fees$14,17531%
- Travel & lodging$6,21713%
- Food & beverage$13,55729%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 211 | $30,823 |
| Abiomed | 41 | $10,769 |
| Abbott | 57 | $1,331 |
| Avinger Inc. | 18 | $697 |
| Johnson & Johnson | 26 | $461 |
| Shockwave Medical, Inc | 4 | $448 |
| Penumbra, Inc. | 7 | $354 |
| Edwards Lifesciences | 9 | $270 |
| Medtronic | 4 | $153 |
| Amgen | 9 | $134 |
| Novartis | 7 | $116 |
| W. L. Gore & Associates, Inc. | 7 | $114 |
| Angiodynamics, Inc. | 3 | $106 |
| AstraZeneca | 2 | $101 |
| Asahi Intecc USA, Inc. | 3 | $96 |
| Biosense Webster, Inc. | 3 | $96 |
| Pfizer | 6 | $79 |
| Terumo Medical Corporation | 3 | $75 |
| Livanova USA, Inc. | 2 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $50 |
| Biotronik Inc. | 2 | $43 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Cordis US CORP. | 1 | $13 |
| Cvrx, Inc. | 1 | $11 |
| Elutia, Inc. | 1 | $11 |
| Cardinal Health 200 LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$9,523
- GENERAL VASCULAR INTERVENTION$8,996
- ELUVIA$6,498
- GENERAL - THERAPIES$2,239
- EKOSONIC$1,803
- PANTHERIS$320
- AVVIGO Guidance System$252
- SOLYX$215
- Vascular Lithotripsy$199
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$195
- Penumbra System$130
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$127
- Indigo System$113
- GENERAL - STENTS$101
How this compares
$46,462 in reported general payments places this provider in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 451 | $323,372 |
| Repatha SureclickEvolocumab | 109 | $125,184 |
| EntrestoSacubitril/Valsartan | 149 | $120,481 |
| XareltoRivaroxaban | 100 | $60,484 |
| JardianceEmpagliflozin | 79 | $54,559 |
| Praluent PenAlirocumab | 31 | $39,200 |
| BrilintaTicagrelor | 27 | $17,512 |
| Ranolazine ErRanolazine | 315 | $14,249 |
| Prasugrel Hcl | 139 | $9,095 |
| ClopidogrelClopidogrel Bisulfate | 1,143 | $8,991 |
| VascepaIcosapent Ethyl | 20 | $8,601 |
| Atorvastatin Calcium | 686 | $5,872 |
| Rosuvastatin Calcium | 564 | $5,545 |
| Ezetimibe | 248 | $5,065 |
| Metoprolol Succinate | 439 | $4,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $323,372451 claims |
| NovartisEntresto | $116 | $120,481149 claims |
| Johnson & JohnsonXarelto | $461 | $60,484100 claims |
| Boehringer IngelheimJardiance | $15 | $54,55979 claims |
| AstraZenecaBrilinta | $101 | $17,51227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Jonesboro
- Barry TedderJonesboro$130K
- Dharmendra PatelJonesboro$36K
- Nephertiti EfeovbokhanJonesboro$15K
- Matthew HausteinJonesboro$8K
- Anthony WhiteJonesboro$8K
- Jaime ChavezJonesboro$7K
- Mahesh AradhyaJonesboro$5K
- Michael IsaacsonJonesboro$5K
- Ian CawichLittle Rock$294K
- Harvinder DodEl Dorado$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.